Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Larotrectinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 29,743Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Approval of Vitrakvi for NTRK GeneFusion-Positive Tumors
    FDA Grants Approval of Vitrakvi for NTRK GeneFusion-Positive Tumors

    10 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250409395229/en/U.S.-FDA-Grants-Full-Approval-of-VITRAKVI-larotrectinib-for-Adult-and-Pediatric-Patients-with-NTRK-Gene-Fusion-Positive-Solid-Tumors

    BUSINESSWIRE
    10 Apr 2025
    Share Share
    Bayer To Present New Prostate Cancer Data At ESMO 2024
    Bayer To Present New Prostate Cancer Data At ESMO 2024

    05 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240905157527/en

    BUSINESSWIRE
    05 Sep 2024
    Share Share
    Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination
    Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

    21 Nov 2023

    // FDA

    https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bayer-issues-voluntary-recall-nationwide-vitrakvir-larotrectinib-oral-solution-20-mgml-due-presence

    FDA
    21 Nov 2023
    Share Share
    Bayer recalls one lot of cancer drug Vitrakvi due to contamination
    Bayer recalls one lot of cancer drug Vitrakvi due to contamination

    18 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231117781825/en

    BUSINESSWIRE
    18 Nov 2023
    Share Share
    Latest Vitrakvi Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy
    Latest Vitrakvi Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy

    02 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230601006134/en

    BUSINESSWIRE
    02 Jun 2023
    Share Share
    Tissue-agnostic drug development: FDA oncology center offers draft guidance
    Tissue-agnostic drug development: FDA oncology center offers draft guidance

    18 Oct 2022

    // Zachary Brennan ENDPTS

    https://endpts.com/tissue-agnostic-drug-development-fda-oncology-center-offers-draft-guidance/

    Zachary Brennan ENDPTS
    18 Oct 2022
    Share Share